Developer docs
API playgroundTry for free, no card

Search company profiles

Affibody

Full company profile

uuid00024ch

Namestring
Affibody
Legal namestring
Affibody AB
Websiteurl
affibody.se
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Affibody AB is a Swedish clinical-stage biotechnology company headquartered in Stockholm, founded in 1998 to develop therapeutics and diagnostics based on its proprietary Affibody molecule platform. Affibody molecules are small protein scaffolds of approximately 6 kDa—significantly smaller than conventional antibodies (~150 kDa)—engineered to bind specific target antigens with high affinity. The company leverages this miniaturization advantage for superior tumor penetration and rapid clearance from circulation, properties well-suited to radioligand therapy where a radioactive payload is delivered directly to cancer cells.

The company's lead clinical asset is ABY-271, a Lutetium-177 (Lu-177)-conjugated Affibody molecule targeting HER2 for the treatment of HER2-positive metastatic breast cancer in patients resistant to conventional HER2 therapies. ABY-271 entered first-in-human Phase 1 dosing in October 2025, and by December 2025 the Trial Review Committee recommended advancement to a second cohort evaluating higher radioactivity levels based on positive safety, tolerability, and biodistribution data showing low uptake in kidneys and critical organs. Beyond HER2, the pipeline extends to PSMA and GPC3-targeted radioligand therapies, and the platform has been applied to non-oncology indications through out-licensing arrangements.

Affibody operates a hybrid business model combining out-licensed partnerships with retained internal clinical development. The company holds an out-licensing agreement with Rallybio for RLYB116 (a complement factor 5 inhibitor that reported positive Phase 1 PK/PD data in February 2026), generating potential milestone and royalty revenue. It has also secured vertical supply chain integration via a Letter of Intent with SHINE Technologies for non-carrier-added Lu-177 to support clinical and potentially commercial supply. The company is funded primarily through a €20 million EIB loan (December 2022, structured in three tranches) and historical venture and bank financing, and has no commercial product revenue at present. Clinical operations span Sweden and Germany.

Short descriptiontext

Affibody is a Swedish clinical-stage biotech developing radioligand therapies using its proprietary ~6 kDa Affibody molecule platform, with lead candidate ABY-271 in Phase 1 trials for HER2-positive metastatic breast cancer and a broader pipeline targeting PSMA and GPC3.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radioligand therapy, protein scaffolds, cancer therapeutics, biopharmaceuticals, targeted therapy
Industry1 code
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Royalties
TypeLicensing Royalties
Description

Affibody licenses its technology and drug candidates to partners such as Rallybio for RLYB116, generating potential royalty streams from successful commercialization.

news.cision.com
2Pharmaceutical Product Sales (Future)
TypeOne Time License
Description

Once clinical candidates receive regulatory approval, the company intends to commercialize radioligand therapies directly or through partnerships, generating product revenue.

drug-dev.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Affibody AB is a Swedish clinical-stage biopharmaceutical company developing radioligand therapies and other protein-based therapeutics for cancer and inflammatory diseases. Its proprietary Affibody molecule platform consists of small (~6 kDa) engineered protein scaffolds that can be conjugated to therapeutic or diagnostic radionuclides (e.g., Lu-177) and targeted to disease-specific biomarkers such as HER2, PSMA, and GPC3. The lead clinical candidate, ABY-271, is a Lu-177-conjugated Affibody molecule in Phase 1 evaluation for HER2-positive metastatic breast cancer. The company also out-licenses its platform (e.g., Rallybio's RLYB116 complement inhibitor).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 1 clinical study demonstrated tumor targeting and favorable safety profile with low uptake in kidneys and other critical organs
+1 more record
Product overview1 text field

Affibody AB is a Swedish biotech company developing radioligand therapies for cancer treatment. The company's core offering centers on its Affibody molecules platform — small protein scaffolds that can be engineered to target specific biomarkers — which serves as the foundation for its lead product candidate ABY-271. ABY-271 is a HER2-targeted Lu-177-conjugated radioligand therapy in Phase 1 clinical evaluation for HER2-positive metastatic breast cancer, with the company also holding partnerships for therapeutic radionuclide supply (SHINE Technologies) and out-licensing arrangements (Rallybio for complement programs).

Product and service2 records
1ABY-271
CategoryRadioligand therapy candidate
2Affibody Molecules
CategoryBiopharmaceutical technology platform
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-19
Description

Affibody AB signed a Letter of Intent with SHINE Technologies for the supply of non-carrier-added Lutetium-177 to support the company's radioligand therapy clinical research and development activities. The agreement covers lead program ABY-271 and additional pipeline programs, with potential extension to commercial Lu-177 supply should ABY-271 successfully progress to commercialization.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-02-18
Description

Affibody's licensee Rallybio announced positive Phase 1 PK/PD clinical study results for RLYB116, a once-weekly subcutaneously injected complement factor 5 inhibitor. Rallybio plans to initiate a Phase 2 clinical study in platelet transfusion refractoriness in H2 2026 with potential topline data in 2027.

Strategic tierMinorTypeOthersAnnounced on2025-06-16
Description

Clarivate released a Companies to Watch report profiling Affibody as one of six radioligand therapy innovators advancing precision oncology, highlighting the company among emerging players alongside Alpha-9 Oncology, Ariceum Therapeutics, Convergent Therapeutics, Perspective Therapeutics, and PRECIRIX.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Commercial-stage leader in radioligand therapy with Pluvicto (177Lu-PSMA-617) and Lutathera approved; sets the therapeutic-class standard Affibody's HER2 program must compete against and validates commercial demand for Lu-177-conjugated targeted radioligands.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing PSMA-targeted radioligand therapy for prostate cancer; closely comparable to Affibody as a small-format, target-focused radioligand developer.

TypeDirect peer
Description

Clinical-stage radioconjugate developer using targeted alpha therapy; acquired by AstraZeneca for $2.4B, offering a comparable radioligand-therapy peer and exit-precedent for Affibody.

TypeDirect peer
Description

Developer of radiotheranostics for cancer, including PSMA and somatostatin receptor-targeted agents; comparable European-headquartered radioligand peer profiled alongside Affibody in Clarivate's Companies to Watch.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing actinium-225-based radioligand therapies; acquired by BMS for $4.1B, providing a direct valuation and exit benchmark for independent radioligand developers like Affibody.

TypeBroad incumbent
Description

Commercial radiopharmaceutical company with established diagnostic imaging agents and a growing radioligand therapy pipeline; broad incumbent peer providing market and pricing benchmarks for Affibody's imaging and therapy programs.

TypeDirect peer
Description

Clinical-stage radiopharmaceutical company developing targeted alpha and beta radioligand therapies for solid tumors; profiled alongside Affibody in Clarivate's Companies to Watch report as a peer radioligand innovator.

TypeDirect peer
Description

Belgian clinical-stage biotech developing targeted radiopharmaceuticals using single-domain antibody scaffolds; highly comparable to Affibody in combining small-format targeting scaffolds with radioisotope payloads.

TypeDirect peer
Description

Clinical-stage company developing targeted alpha and beta-emitting radiopharmaceuticals for solid tumors; comparable peer in the radioligand therapy innovation cohort alongside Affibody.

TypeEmerging player
Description

Commercial-stage radiopharmaceutical company with approved PSMA-PET imaging agent and pipeline radioligand therapies; relevant comparable as a small-cap public radiopharma peer validating the commercial path Affibody is targeting.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Affibody

Radiopharmaceuticalsaffibody.se

Affibody is a Swedish clinical-stage biotech developing radioligand therapies using its proprietary ~6 kDa Affibody molecule platform, with lead candidate ABY-271 in Phase 1 trials for HER2-positive metastatic breast cancer and a broader pipeline targeting PSMA and GPC3.

What Affibody does

Affibody AB is a Swedish clinical-stage biotechnology company headquartered in Stockholm, founded in 1998 to develop therapeutics and diagnostics based on its proprietary Affibody molecule platform. Affibody molecules are small protein scaffolds of approximately 6 kDa—significantly smaller than conventional antibodies (~150 kDa)—engineered to bind specific target antigens with high affinity. The company leverages this miniaturization advantage for superior tumor penetration and rapid clearance from circulation, properties well-suited to radioligand therapy where a radioactive payload is delivered directly to cancer cells.

The company's lead clinical asset is ABY-271, a Lutetium-177 (Lu-177)-conjugated Affibody molecule targeting HER2 for the treatment of HER2-positive metastatic breast cancer in patients resistant to conventional HER2 therapies. ABY-271 entered first-in-human Phase 1 dosing in October 2025, and by December 2025 the Trial Review Committee recommended advancement to a second cohort evaluating higher radioactivity levels based on positive safety, tolerability, and biodistribution data showing low uptake in kidneys and critical organs. Beyond HER2, the pipeline extends to PSMA and GPC3-targeted radioligand therapies, and the platform has been applied to non-oncology indications through out-licensing arrangements.

Affibody operates a hybrid business model combining out-licensed partnerships with retained internal clinical development. The company holds an out-licensing agreement with Rallybio for RLYB116 (a complement factor 5 inhibitor that reported positive Phase 1 PK/PD data in February 2026), generating potential milestone and royalty revenue. It has also secured vertical supply chain integration via a Letter of Intent with SHINE Technologies for non-carrier-added Lu-177 to support clinical and potentially commercial supply. The company is funded primarily through a €20 million EIB loan (December 2022, structured in three tranches) and historical venture and bank financing, and has no commercial product revenue at present. Clinical operations span Sweden and Germany.

Affibody firmographics

Firmographics
Name
Affibody
Legal name
Affibody AB
Website
https://affibody.se
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
51–100 employees
Short description
Affibody is a Swedish clinical-stage biotech developing radioligand therapies using its proprietary ~6 kDa Affibody molecule platform, with lead candidate ABY-271 in Phase 1 trials for HER2-positive metastatic breast cancer and a broader pipeline targeting PSMA and GPC3.
Ownership category
akta.pro rank

Affibody industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Radioligand therapy
  • Protein scaffolds
  • Cancer therapeutics
  • Biopharmaceuticals
  • Targeted therapy

Where Affibody is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Affibody business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Licensing Royalties: Affibody licenses its technology and drug candidates to partners such as Rallybio for RLYB116, generating potential royalty streams from successful commercialization.
  2. Pharmaceutical Product Sales (Future): Once clinical candidates receive regulatory approval, the company intends to commercialize radioligand therapies directly or through partnerships, generating product revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Affibody product offering

Product offering

Core offering

Affibody AB is a Swedish clinical-stage biopharmaceutical company developing radioligand therapies and other protein-based therapeutics for cancer and inflammatory diseases. Its proprietary Affibody molecule platform consists of small (~6 kDa) engineered protein scaffolds that can be conjugated to therapeutic or diagnostic radionuclides (e.g., Lu-177) and targeted to disease-specific biomarkers such as HER2, PSMA, and GPC3. The lead clinical candidate, ABY-271, is a Lu-177-conjugated Affibody molecule in Phase 1 evaluation for HER2-positive metastatic breast cancer. The company also out-licenses its platform (e.g., Rallybio's RLYB116 complement inhibitor).

Product overview

Affibody AB is a Swedish biotech company developing radioligand therapies for cancer treatment. The company's core offering centers on its Affibody molecules platform — small protein scaffolds that can be engineered to target specific biomarkers — which serves as the foundation for its lead product candidate ABY-271. ABY-271 is a HER2-targeted Lu-177-conjugated radioligand therapy in Phase 1 clinical evaluation for HER2-positive metastatic breast cancer, with the company also holding partnerships for therapeutic radionuclide supply (SHINE Technologies) and out-licensing arrangements (Rallybio for complement programs).

Differentiator

Problem solved

Functional benefit

Products and services

  • ABY-271
  • Affibody Molecules

Quantifiable outcome

  • Phase 1 clinical study demonstrated tumor targeting and favorable safety profile with low uptake in kidneys and other critical organs
  • +1 more outcomes

Companies that use Affibody

Customer profile

Segments2 records

Ideal customer profiles2 records

Affibody technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Affibody partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • SHINE TechnologiescoreTechnology or Integration · 19 February 2026Affibody AB signed a Letter of Intent with SHINE Technologies for the supply of non-carrier-added Lutetium-177 to support the company's radioligand therapy clinical research and development activities. The agreement covers lead program ABY-271 and additional pipeline programs, with potential extension to commercial Lu-177 supply should ABY-271 successfully progress to commercialization.
  • RallybiocoreOEM/ Whitelabel/ Licensing Partner · 18 February 2026Affibody's licensee Rallybio announced positive Phase 1 PK/PD clinical study results for RLYB116, a once-weekly subcutaneously injected complement factor 5 inhibitor. Rallybio plans to initiate a Phase 2 clinical study in platelet transfusion refractoriness in H2 2026 with potential topline data in 2027.
  • ClarivateminorOthers · 16 June 2025Clarivate released a Companies to Watch report profiling Affibody as one of six radioligand therapy innovators advancing precision oncology, highlighting the company among emerging players alongside Alpha-9 Oncology, Ariceum Therapeutics, Convergent Therapeutics, Perspective Therapeutics, and PRECIRIX.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Affibody competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Commercial-stage leader in radioligand therapy with Pluvicto (177Lu-PSMA-617) and Lutathera approved; sets the therapeutic-class standard Affibody's HER2 program must compete against and validates commercial demand for Lu-177-conjugated targeted radioligands.
  • Lantheus Holdings: Commercial radiopharmaceutical company with established diagnostic imaging agents and a growing radioligand therapy pipeline; broad incumbent peer providing market and pricing benchmarks for Affibody's imaging and therapy programs.

Direct peers

  • Convergent Therapeutics: Clinical-stage radiopharmaceutical company developing PSMA-targeted radioligand therapy for prostate cancer; closely comparable to Affibody as a small-format, target-focused radioligand developer.
  • Fusion Pharmaceuticals (AstraZeneca): Clinical-stage radioconjugate developer using targeted alpha therapy; acquired by AstraZeneca for $2.4B, offering a comparable radioligand-therapy peer and exit-precedent for Affibody.
  • Ariceum Therapeutics: Developer of radiotheranostics for cancer, including PSMA and somatostatin receptor-targeted agents; comparable European-headquartered radioligand peer profiled alongside Affibody in Clarivate's Companies to Watch.
  • RayzeBio (Bristol Myers Squibb): Clinical-stage radiopharmaceutical company developing actinium-225-based radioligand therapies; acquired by BMS for $4.1B, providing a direct valuation and exit benchmark for independent radioligand developers like Affibody.
  • Alpha-9 Oncology: Clinical-stage radiopharmaceutical company developing targeted alpha and beta radioligand therapies for solid tumors; profiled alongside Affibody in Clarivate's Companies to Watch report as a peer radioligand innovator.
  • PRECIRIX: Belgian clinical-stage biotech developing targeted radiopharmaceuticals using single-domain antibody scaffolds; highly comparable to Affibody in combining small-format targeting scaffolds with radioisotope payloads.
  • Perspective Therapeutics: Clinical-stage company developing targeted alpha and beta-emitting radiopharmaceuticals for solid tumors; comparable peer in the radioligand therapy innovation cohort alongside Affibody.

Emerging players

  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with approved PSMA-PET imaging agent and pipeline radioligand therapies; relevant comparable as a small-cap public radiopharma peer validating the commercial path Affibody is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Affibody social profiles

Digital presence

Affibody financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Affibody leadership team

Management profile

Number of profiles

Profiles2 records

Affibody funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Affibody M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Affibody

What does Affibody do?

Affibody AB is a Swedish clinical-stage biopharmaceutical company developing radioligand therapies and other protein-based therapeutics for cancer and inflammatory diseases. Its proprietary Affibody molecule platform consists of small (~6 kDa) engineered protein scaffolds that can be conjugated to therapeutic or diagnostic radionuclides (e.g., Lu-177) and targeted to disease-specific biomarkers such as HER2, PSMA, and GPC3. The lead clinical candidate, ABY-271, is a Lu-177-conjugated Affibody molecule in Phase 1 evaluation for HER2-positive metastatic breast cancer. The company also out-licenses its platform (e.g., Rallybio's RLYB116 complement inhibitor).

Is Affibody a public or private company?

Affibody is a private company. It is classified as unknown and is currently operating.

When was Affibody founded?

Affibody was founded in 1998. It employs 51 to 100 people.

Where is Affibody based?

Affibody is headquartered in Stockholm, Sweden, in the Europe region.

How does Affibody make money?

Two revenue lines are on record. Licensing Royalties are the primary driver. The others are pharmaceutical Product Sales (Future).

Who are Affibody's main competitors?

Broad incumbents on record are Novartis and Lantheus Holdings. Direct peers are Convergent Therapeutics, Fusion Pharmaceuticals (AstraZeneca), Ariceum Therapeutics, RayzeBio (Bristol Myers Squibb), Alpha-9 Oncology, PRECIRIX and Perspective Therapeutics. Telix Pharmaceuticals is listed as an emerging player.

Does Affibody have an API?

No public API is recorded for Affibody.

What industry is Affibody in?

Affibody's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAffibody Establishes Scientific Advisory Board with Appointment of Leading Radiopharmaceutical Experts Oliver Sartor, Ken Herrmann and Peter BernhardtAffibody Medical AB announced the establishment of a Scientific Advisory Board to guide its radioligand therapy pipeline. The board, chaired by Jonathan Knowles, includes Oliver Sartor, Ken Herrmann, and Peter Bernhardt, experts in oncology and radiopharmaceutical development. CEO David Bejker said their guidance will be invaluable as the company advances its pipeline.Business & FinancialPsoriatic Arthritis Market Size, Share, Trends, And Growth Analysis: Strong Expansion Expected By 2036 Bristol Myers Squibb, UBC, Sun Pharma, Affibody Medical, Johnson & Johnson, Takeda, AltrubioDelveInsight forecasts the psoriatic arthritis market to grow to about $15 billion by 2036, with a significant CAGR from 2022 to 2036. Recent clinical trial results from Bristol Myers Squibb, Affibody, and Sun Pharma support pipeline activity. The market is driven by rising disease prevalence and awareness.FierceBiotechAffibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejectionAffibody re-licensed izokibep after Acelyrin's merger, presenting Phase 3 data at EULAR showing strong efficacy in psoriatic arthritis. The IL-17A inhibitor previously failed in hidradenitis suppurativa, but plans are back on track. Affibody is seeking a new home for the drug, with ongoing discussions.ForbesPrecision Radiation Therapy Could Offer New Hope For Hard-To-Treat CancersRadionuclide therapy, a class of cancer medicines that deliver radioactive atoms directly to tumors with precision, has seen a growing number of regulatory approvals over the past 13 years, with the market projected to reach $10.7 billion by 2030. Key players including Novartis, Bayer, and Affibody are developing treatments using cancer-specific biomarkers such as PSMA and GPC3 to enable highly targeted radiation delivery. A UK-based biotech called Nuclide Therapeutics is planning a clinical trial in lung cancer patients using a two-stage diagnostic and therapeutic approach, while researchers suggest these therapies could eventually move from last-line to first-line cancer treatment.Drug Development and DeliveryRADIOLIGAND THERAPIES - Affibody Molecules: A Versatile Approach to RadiopharmaSwedish biotech Affibody AB announced in December 2025 promising initial results from the first cohort of its Phase 1 clinical study for lead candidate ABY-271, a radioligand therapy for HER2-positive metastatic breast cancer, demonstrating tumor targeting and a favorable safety profile with low uptake in kidneys and other critical organs. The company decided to advance the trial to its second part to evaluate higher radioactivity levels, building on the first-in-human dosing that began in October 2025. Affibody's Affibody molecules, which are significantly smaller than antibodies, offer advantages in tumor penetration and rapid clearance, positioning the therapy as a potential treatment option for patients who have become resistant to conventional HER2 therapies.news.cision.comAffibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177Affibody AB has signed a Letter of Intent with SHINE Technologies for the supply of non-carrier-added Lutetium-177 to support the company's radioligand therapy clinical research and development activities. The agreement will cover Affibody's lead program ABY-271, a HER2-targeted Lu-177-conjugated molecule currently in Phase 1 evaluation for metastatic breast cancer, as well as additional pipeline programs. The parties may explore extending the arrangement to include commercial Lu-177 supply should ABY-271 successfully progress to commercialization.news.cision.comAffibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal ComplementAffibody's licensee Rallybio announced positive results from its Phase 1 PK/PD clinical study of RLYB116, a once-weekly subcutaneously injected complement factor 5 inhibitor, demonstrating complete and sustained inhibition of terminal complement at both 150mg and 300mg doses with favorable tolerability and no gastrointestinal side effects. The study enrolled 16 healthy volunteers across two cohorts in a 4-week treatment with 10-week follow-up period. Rallybio plans to initiate a Phase 2 clinical study in platelet transfusion refractoriness in H2 2026 with potential topline data in 2027.news.cision.comAffibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient DataAffibody AB announced that its Trial Review Committee has recommended advancing the Phase I clinical study of its radioligand therapy candidate ABY-271 to the second part, where higher radioactivity levels will be evaluated. This decision follows initial patient data demonstrating a favorable safety profile and encouraging biodistribution with low uptake in critical organs for HER2-positive metastatic breast cancer. The company plans to submit a protocol amendment to the European Medicines Agency, with the next phase expected to start in the first half of 2026.PR NewswireAffibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient DataAffibody AB announced that its Trial Review Committee has recommended advancing the Phase I clinical study with radioligand therapy candidate ABY-271 for HER2-positive metastatic breast cancer to Part B, based on favorable safety and biodistribution data from the first patient cohort. The study demonstrated tumor targeting with a favorable safety profile and low uptake in kidneys and other critical organs, with Part B expected to begin in H1 2026 evaluating higher radioactivity levels. This marks an important milestone for Affibody's radiopharmaceutical platform, validating its Affibody® molecule technology for targeted radiotherapeutics.Stock TitanRadioligand Therapy Leaders: 6 Companies Reshaping $13B Cancer Treatment MarketClarivate released a Companies to Watch report identifying six radioligand therapy innovators, including Affibody, Alpha-9 Oncology, and Convergent Therapeutics. The report highlights the $13B global radiopharmaceutical market projected to grow within a decade, with notable acquisitions like Bristol Myers Squibb's $4.1B purchase of RayzeBio.